316 related articles for article (PubMed ID: 25227702)
21. Targeting the innate immune system in pediatric and adult AML.
Perzolli A; Koedijk JB; Zwaan CM; Heidenreich O
Leukemia; 2024 Jun; 38(6):1191-1201. PubMed ID: 38459166
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell vaccination in acute myeloid leukemia.
Anguille S; Willemen Y; Lion E; Smits EL; Berneman ZN
Cytotherapy; 2012 Jul; 14(6):647-56. PubMed ID: 22686130
[TBL] [Abstract][Full Text] [Related]
23. Alterations of T-cell-mediated immunity in acute myeloid leukemia.
Li Z; Philip M; Ferrell PB
Oncogene; 2020 Apr; 39(18):3611-3619. PubMed ID: 32127646
[TBL] [Abstract][Full Text] [Related]
24. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acute myeloid leukemia by directly targeting both leukemia stem cells and oncogenic molecule with specific scFv-immunolipoplexes as a deliverer.
Wang GP; Qi ZH; Chen FP
Med Hypotheses; 2008; 70(1):122-7. PubMed ID: 17566667
[TBL] [Abstract][Full Text] [Related]
26. Immune escape and immunotherapy of acute myeloid leukemia.
Vago L; Gojo I
J Clin Invest; 2020 Apr; 130(4):1552-1564. PubMed ID: 32235097
[TBL] [Abstract][Full Text] [Related]
27. Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
Robin M; Schlageter MH; Chomienne C; Padua RA
Cancer Immunol Immunother; 2005 Oct; 54(10):933-43. PubMed ID: 15889256
[TBL] [Abstract][Full Text] [Related]
28. Targeting of CD44 eradicates human acute myeloid leukemic stem cells.
Jin L; Hope KJ; Zhai Q; Smadja-Joffe F; Dick JE
Nat Med; 2006 Oct; 12(10):1167-74. PubMed ID: 16998484
[TBL] [Abstract][Full Text] [Related]
29. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
30. The potential role of the thymus in immunotherapies for acute myeloid leukemia.
Hino C; Xu Y; Xiao J; Baylink DJ; Reeves ME; Cao H
Front Immunol; 2023; 14():1102517. PubMed ID: 36814919
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic cancer vaccine therapy for acute myeloid leukemia.
Wu M; Wang S; Chen JY; Zhou LJ; Guo ZW; Li YH
Immunotherapy; 2021 Jul; 13(10):863-877. PubMed ID: 33955237
[TBL] [Abstract][Full Text] [Related]
32. A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.
Bolandi SM; Pakjoo M; Beigi P; Kiani M; Allahgholipour A; Goudarzi N; Khorashad JS; Eiring AM
Cells; 2021 Oct; 10(11):. PubMed ID: 34831055
[TBL] [Abstract][Full Text] [Related]
33. Advances in immunotherapy for pediatric acute myeloid leukemia.
Bonifant CL; Velasquez MP; Gottschalk S
Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
[TBL] [Abstract][Full Text] [Related]
34. Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.
Yuan J; Zhang J; Zhao B; Liu F; Liu T; Duan Y; Chen Y; Chen X; Zou Y; Zhang L; Guo Y; Yang W; Yang Y; Wei J; Zhu X; Zhang Y
Cancer Lett; 2024 Aug; 596():217018. PubMed ID: 38844062
[TBL] [Abstract][Full Text] [Related]
35. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment.
Serroukh Y; Hébert J; Busque L; Mercier F; Rudd CE; Assouline S; Lachance S; Delisle JS
Blood Rev; 2023 Jan; 57():100991. PubMed ID: 35941029
[TBL] [Abstract][Full Text] [Related]
36. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia.
Serrano-López J; Sanchez-Garcia J; Serrano J; Alvarez-Rivas MA; Garcia-Castellano JM; Roman-Gomez J; de la Rosa O; Herrera-Arroyo C; Torres-Gomez A
Transfusion; 2011 Jul; 51(7):1546-55. PubMed ID: 21303373
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.
Lee JJ; Kook H; Park MS; Nam JH; Choi BH; Song WH; Park KS; Lee IK; Chung IJ; Hwang TJ; Kim HJ
J Clin Apher; 2004; 19(2):66-70. PubMed ID: 15274198
[TBL] [Abstract][Full Text] [Related]
38. Developmental approaches in immunological control of acute myelogenous leukaemia.
Torelli GF; Orsini E; Guarini A; Kell J; Foà R
Best Pract Res Clin Haematol; 2001 Mar; 14(1):189-209. PubMed ID: 11355931
[TBL] [Abstract][Full Text] [Related]
39. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
Lamble AJ; Kosaka Y; Laderas T; Maffit A; Kaempf A; Brady LK; Wang W; Long N; Saultz JN; Mori M; Soong D; LeFave CV; Huang F; Adams H; Loriaux MM; Tognon CE; Lo P; Tyner JW; Fan G; McWeeney SK; Druker BJ; Lind EF
Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14331-14341. PubMed ID: 32513686
[TBL] [Abstract][Full Text] [Related]
40. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
